| Item type |
文献 / Documents(1) |
| 公開日 |
2025-03-03 |
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.2147/TCRM.S72299 |
|
|
関連名称 |
10.2147/TCRM.S72299 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| タイトル |
|
|
タイトル |
Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension |
| 著者 |
八木, 秀介
Takashima, Akira
Mitsugi, Minoru
Wada, Toshihiro
Hotchi, Junko
粟飯原, 賢一
原, 知也
Ishida, Masayoshi
福田, 大受
伊勢, 孝之
山口, 浩司
Tobiume, Takeshi
岩瀬, 俊
山田, 博胤
添木, 武
若槻, 哲三
島袋, 充生
赤池, 雅史
佐田, 政隆
|
| 抄録 |
|
|
内容記述 |
Background: Hypertension is one of the major risk factors for cardiovascular and cerebrovascular disease and mortality. Patients who receive insufficient doses of antihypertensive agents or who are poorly adherent to multidrug treatment regimens often fail to achieve adequate blood pressure (BP) control. The aim of this study was to determine the efficacy of an angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB) combination tablet containing a regular dose of irbesartan (100 mg) and a high dose of amlodipine (10 mg) with regard to lowering BP and other risk factors for cardiovascular disease.
Methods: We retrospectively evaluated data from 68 patients with essential hypertension whose treatment regimen was changed either from combination treatment with an independent ARB and a low-dose or regular-dose CCB or from a combination tablet of ARB and a low-dose or regular-dose CCB to a combination tablet containing amlodipine 10 mg and irbesartan 100 mg, because of incomplete BP control. Previous treatments did not include irbesartan as the ARB.
Results: The combination tablet decreased systolic and diastolic BP. In addition, it significantly decreased serum uric acid, low-density lipoprotein cholesterol, and increased high-density lipoprotein cholesterol levels, independent of the BP-lowering effect. Treatment with the combination tablet did not affect serum triglycerides, plasma glucose, glycated hemoglobin, serum potassium or creatinine levels, or the urinary albumin excretion rate.
Conclusion: The combination tablet containing amlodipine 10 mg and irbesartan 100 mg had a greater BP-lowering effect than an ARB and a low-dose or regular-dose CCB. In addition, the combination tablet had more favorable effects on serum uric acid, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol levels in patients with hypertension. |
| キーワード |
|
|
主題 |
blood pressure |
| キーワード |
|
|
主題 |
combination tablet |
| キーワード |
|
|
主題 |
uric acid |
| キーワード |
|
|
主題 |
low-density lipoprotein cholesterol |
| キーワード |
|
|
主題 |
high-density lipoprotein cholesterol |
| 書誌情報 |
en : Therapeutics and Clinical Risk Management
巻 11,
p. 83-88,
発行日 2015-01-12
|
| 収録物ID |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
11766336 |
| 収録物ID |
|
|
収録物識別子タイプ |
EISSN |
|
収録物識別子 |
1178203X |
| 出版者 |
|
|
出版者 |
Dove Medical Press |
| 権利情報 |
|
|
権利情報 |
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php |
| EID |
|
|
識別子 |
289160 |
| 言語 |
|
|
言語 |
eng |
tcrm_11_83.pdf (292 KB)
